Breathe BioMedical Inc. has a Form F-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-07-05. Amendments on record here: 5. It asked for the registration statement to be withdrawn on 2024-10-28. Each fact below is quoted from the filing named with it.
What the filings say
Listing
We have applied to list our common shares on the Nasdaq Capital Market under the symbol “BRTH”.From the F-1/A filed 2024-09-30
Price range
We expect the initial public offering price to be between $4.00 and $6.00 per share.From the F-1/A filed 2024-09-30
Use of proceeds
We intend to use the net proceeds from this offering to fund research and development of our product candidates and development programs for working capital and other general corporate purposes and for the repayment of $682,019 in outstanding indebtedness.From the F-1/A filed 2024-09-30
Net loss or income
Our net loss was Cdn$8,362,319, Cdn$4,458,293 and Cdn$3,970,833 for the years ended December 31, 2023, 2022 and 2021, respectively.From the F-1/A filed 2024-09-30
Withdrawal
Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “ Securities Act ”), Breathe BioMedical Inc. (the “ Company ”) hereby respectfully requests that the U.S. Securities and Exchange Commission (the “ Commission ”) consent to the withdrawal, effective as of the date hereof or at the earliest practicable date hereafter, of the Company’s Registration Statement on Form F-1 (File No. 333-280034) together with all exhibits and amendments thereto (collectively, the “ Registration Statement ”) initially filed with the Commission on June 7, 2024 and most recently amended on October 10, 2024.From the RW filed 2024-10-28
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-07-05 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-07-26 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-09-13 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-09-30 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-10-10 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-10-28 | Request to withdraw a registration (Form F-1) | RW |
Tools for this story
Each opens in a new tab, filled in for Breathe BioMedical Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.